INVO Fertility, Inc..
IVF.US | Medical and dental practice activities
INVO Fertility, Inc. operates as a fertility company. It focuses on providing affordable and accessible fertility treatment solutions. The company has developed the INVOcell, an in vivo culture device used in infertility treatment. INVO Fertility partners with clinics to offer the INVOcell procedure...Show More
Better Health for All
30
The company's core product, INVOcell, is an FDA-cleared intravaginal culture system for infertility treatment, offering a clinical pregnancy success rate of approximately 52.1% (SART 2018), comparable to traditional IVF and significantly higher than IUI.
1
This indicates that the entire business is devoted to health improvement, delivering exceptional health benefits. The INVOcell treatment costs $5,000-$8,000 per cycle, representing a 50-60% reduction compared to traditional IVF at $12,000-$15,000 per cycle, making it significantly more affordable.
2
The company claims to address a significantly underserved market globally, with over 90% of infertile couples remaining untreated, and aims to 'democratize fertility care.'
3
It provides expanded hands-on training and clinical support for physicians and embryologists to integrate INVOcell into clinical practices, and plans targeted educational campaigns to increase market awareness.
4
Fair Money & Economic Opportunity
0
INVO Fertility, Inc. operates as a fertility company, providing a medical device (INVOcell) and related services to fertility clinics.
1
The company does not offer lending, deposit, or other consumer financial services.
2
Therefore, KPIs related to financial products, such as underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives, data accessibility, fair lending compliance, wealth building outcomes, financial literacy initiatives, debt burden ratio, geographic inclusion, and product simplicity, are not applicable to its core business model. No evidence was found regarding profit reinvestment in community finance or profit-sharing with underserved communities.
3
Fair Pay & Worker Respect
0
No specific, quantitative data points were found in the provided articles for IVF.US (INVO Fertility, Inc.) for any of the 'Fair Pay & Worker Respect' KPIs.
1
was disregarded as it pertains to 'Invo Healthcare' and not the company under assessment.
2
provided CEO compensation but lacked median employee compensation, preventing the calculation of the CEO to median pay ratio. Information regarding living wage coverage, collective bargaining share, safety incident rates, pay equity ratios, worker engagement scores, employee turnover rates, labor violation incidents, insecure contract share, or health insurance coverage was not explicitly stated with the required metrics or percentages.
Fair Trade & Ethical Sourcing
0
No evidence available to assess INVO Fertility, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-20
The company determined on September 18, 2024, that its previously issued financial statements needed to be restated due to an accounting error, which was prompted by comments from the SEC.
1
The company has a Clawback Policy, effective October 2, 2023, for mandatory recovery of erroneously awarded incentive compensation in the event of an accounting restatement.
2
Following the 2024 restatement, the Compensation Committee determined that the compensation received by executives during the lookback period would have been the same based on the restated financial statements.
3
The company has adopted a Code of Business Conduct and Ethics, an Insider Trading Policy, and a Hedging Policy.
4
It also has a Related Party Transactions Policy requiring board approval for transactions exceeding the lesser of $120,000 or 1% of the average of total assets at year-end for the last two completed fiscal years.
5
As of December 31, 2024, the company had an outstanding balance of $1,044,786 for related party demand notes and owed $292,338 in accounts payable to related parties, along with $2,123,340 in accrued compensation.
6
Kind to Animals
0
No evidence available to assess INVO Fertility, Inc. on Kind to Animals.
No War, No Weapons
0
No evidence available to assess INVO Fertility, Inc. on No War, No Weapons.
Planet-Friendly Business
0
No evidence available to assess INVO Fertility, Inc. on Planet-Friendly Business.
Respect for Cultures & Communities
0
The provided articles do not contain any specific, concrete data points or facts related to IVF.US's performance on any of the KPIs for "Respect for Cultures & Communities."
1
The articles primarily focus on INVOcell technology, its expansion, pricing, and patent approvals, explicitly stating a lack of data on cultural sensitivity or community engagement metrics.
2
Safe & Smart Tech
-50
INVO Fertility, Inc. has not formally developed and implemented a cybersecurity risk management program.
1
This indicates a lack of a vulnerability management program, despite operating in the fertility sector and handling sensitive health data, which constitutes a high-risk system.
Zero Waste & Sustainable Products
0
No specific, quantitative data is available in the provided articles to assess IVF.US against the 'Zero Waste & Sustainable Products' ethical value. The articles discuss general sustainability needs in the IVF industry or report on studies conducted at other fertility clinics, but do not provide any metrics or initiatives directly attributable to IVF.US.